Omega-3 Supplementation and a Skin Response Test in Schizophrenia Research
This clinical trial explored whether adding omega-3 fatty acid supplements to standard schizophrenia treatment could influence a specific skin test called the niacin skin flush response, which reflects certain fatty acid and inflammatory processes in the body. Researchers compared 99 people with schizophrenia to 30 healthy volunteers and found that people with schizophrenia generally had a weaker (blunted) skin flush response at the start of the study.
Over 21 days, patients were split between standard medication alone or standard medication plus omega-3 supplementation. Both groups saw improvement in psychiatric symptom scores, but only the omega-3 group showed a meaningful improvement in the niacin skin flush response.
Interestingly, when researchers looked specifically at patients who started with the weakest skin flush response, those given omega-3 supplements showed the biggest improvement in this biomarker, along with a trend toward better symptom scores. This suggests the skin flush test might eventually help identify which patients are more likely to benefit from add-on omega-3 supplementation.
What this means for you
This early-stage study suggests that a simple skin test might help identify a subgroup of people with schizophrenia who respond differently to omega-3 supplementation as an add-on to their regular treatment. It’s exploratory research on a specific biomarker, not evidence that omega-3s treat schizophrenia, and any supplementation decisions in this context should be guided by a treating physician.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolSource
Schizophrenia research · 2026-09-03 · DOI: 10.1016/j.schres.2026.08.033
Read the original source ↗This summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.